Why FDA–EMA AI Principles Matter (Part 1)
Overview of Regulatory Alignment The recent joint FDA–EMA guidance “Guiding Principles of Good AI Practice in Drug Development” has sparked conversation across the industry. Do you view it as a major shift or dismiss it as “just another guidance”? The truth usually sits between those extremes. This blog series will examine the signals, which we […]

